In the long and stubborn story of cancer, a quiet moment often comes when a tumor's cells slip into the lymph nodes and begin reshaping the immune defenses that should be guarding them. Researchers at Fudan University Shanghai Cancer Center have traced one such shift to a protein called MOCCI, which in lung cancer cells appears to fuel the energy machinery of mitochondria and, in doing so, to prompt the release of a signal that wears down nearby helper immune cells. The work offers a glimpse of how a tumor's inner metabolism can speak to its neighbors, though the evidence so far rests on a sma
Metabolic Pathway MOCCI Linked to Lung Cancer Spread to Lymph Nodes and Immune Suppression
Tumor cells releasing GDF15 appear to wear down the immune cells beside them
Mark
Start with the basic claim. What is MOCCI doing here?
Mimi
It's a part of mitochondrial complex IV, and in these lung cancer cells it goes along with higher OXPHOS, the mitochondrial energy pathway. Cells with more of it migrated and invaded more, and in mice they spread to lymph nodes more readily.
Mark
And the immune side?
Mimi
Those cells release more GDF15. Nearby Tfh cells carrying TGFBR2 looked more inhibited and showed weaker MHC-II signatures, and neighboring B cells were less activated.
Luke
Careful with the word "exhausted." Is that shown directly?
Mimi
It's the authors' model, built from expression signatures and spatial proximity within 40 micrometers. It's not a demonstration that GDF15 alone disables those cells in patients.
Luke
And the patient numbers?
Mimi
The deep multi-omics work covers just 10 patients. The authors say spatial heterogeneity limited finding shared features.
Mark
But there's a bigger cohort too.
Mimi
Yes, 875 cases. MOCCI was higher with lymph node metastasis and higher nodal status, and in lung adenocarcinoma higher MOCCI went with poorer survival.
Luke
Those are correlations, though. They don't prove MOCCI causes spread in people.
Mimi
Right. The mouse and knockdown experiments carry the causal weight, and those are in cell lines and animals.
Mark
So is it a drug target?
Mimi
Possibly, the authors suggest. Nothing in the report says a treatment exists yet; larger validation comes first.
The Pulse
- Lung cancer cells that reach lymph nodes run an overheated energy engine, and a protein called MOCCI sits at the center of that surge.
- Those cells release GDF15, a signal that slips into the neighboring immune cells and drains their ability to rally against the tumor.
- Researchers mapped tissue from only 10 patients, layering single-cell and spatial sequencing to pin down which immune cells are being silenced and where.
- Mouse experiments and an 875-person clinical cohort point the same direction, yet the team says larger studies must confirm MOCCI as a real therapeutic target.
In the long and stubborn story of cancer, a quiet moment often comes when a tumor's cells slip into the lymph nodes and begin reshaping the immune defenses that should be guarding them. Researchers at Fudan University Shanghai Cancer Center have traced one such shift to a protein called MOCCI, which in lung cancer cells appears to fuel the energy machinery of mitochondria and, in doing so, to prompt the release of a signal that wears down nearby helper immune cells. The work offers a glimpse of how a tumor's inner metabolism can speak to its neighbors, though the evidence so far rests on a small group of patients and awaits wider confirmation before it can guide treatment.
Lung cancer does not stay put. When its cells move into nearby lymph nodes, they enter a crowded neighborhood of immune cells that should be fighting back. Scientists at Fudan University Shanghai Cancer Center set out to watch that encounter closely, and to understand what the invading cells do to the defenders they meet.
Their attention settled on MOCCI, a protein tied to mitochondria, the cell's power plants. In tumor cells that had reached lymph nodes, the energy pathway known as oxidative phosphorylation ran unusually hot, and MOCCI rose and fell with it. When the researchers quieted MOCCI in lung cancer cells, the cells migrated and invaded far less. When they boosted it, the cells burned more energy, released more of the signal GDF15, and spread to lymph nodes in mice.
GDF15 turned out to be the messenger. Within metastatic nodes, helper T cells that normally coordinate immune responses were abundant but worn down. Where those helper cells sat close to GDF15-producing tumor cells, they carried stronger signs of suppression, a pattern that depended on a receptor called TGFBR2. The nearby B cells were likewise muted in their ability to expand.
The clinical picture leaned the same way. Higher MOCCI levels were found in patients whose cancers had reached lymph nodes, and in lung adenocarcinoma, higher levels went with poorer survival. The team is candid that their detailed map rests on just ten patients, and that the variation between samples makes firm conclusions difficult. They have offered their atlas to the field, hoping others will test whether intercepting this metabolic signal could help keep cancer from taking hold in the nodes.
Researchers at Fudan University Shanghai Cancer Center set out to follow lung cancer cells as they travel into lymph nodes, and to see what those cells do to the immune cells they meet there. Their study, published in Cancer Biology & Medicine, centers on a protein called MOCCI, short for Modulator of Cytochrome C Oxidase during Inflammation. Under inflammatory conditions, MOCCI acts as a component of mitochondrial complex IV.
The question behind the work is an old one. Lymph nodes that harbor metastases tend to be immunosuppressive, but how the immune cells inside them become dysfunctional has been poorly characterized. Earlier single-cell studies could infer that tumor cells had rewired their metabolism. What they could not do was show how those rewired cells engage particular immune cells in a specific place within the node. Single-cell RNA sequencing loses spatial context, which limited the analysis of cell-to-cell interactions.
The team, led by corresponding authors Haiquan Chen, Yang Zhang and Xiaoming Zhang, worked with collaborators at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. They analyzed matched samples from 10 patients with lung cancer: primary tumors, metastatic lymph nodes, uninvolved lymph nodes and peripheral blood. They profiled 37 samples by single-cell RNA sequencing and 27 tissue samples by spatial transcriptomics, capturing 671,467 cells across the two datasets. They added T-cell and B-cell receptor sequencing, functional assays, mouse models and an independent clinical cohort.
The tumor cells found in metastatic lymph nodes, which the authors abbreviate PLMCs, showed significant enrichment of the oxidative phosphorylation (OXPHOS) pathway, and MOCCI expression tracked with OXPHOS activity. In PC9 and A549 lung cancer cells, knocking down MOCCI cut migration and invasion by more than 50% compared with controls. Overexpressing it increased mitochondrial respiration and reactive oxygen species generation, and promoted lymph node metastasis in mice.
The cells overexpressing MOCCI also secreted more growth differentiation factor 15, or GDF15, and inhibiting OXPHOS reduced that secretion. This is where the immune picture comes in. T follicular helper (Tfh) cells were more abundant in metastatic lymph nodes than in primary tumors, and they showed dysfunctional antigen-presentation programs. Naive and memory B cells were also enriched, with greater clonal diversity but blunted clonal expansion.
Spatial analysis tied these observations together. Tfh cells expressing transforming growth factor beta receptor 2 (TGFBR2) that sat within 40 micrometers of GDF15-positive PLMCs had stronger inhibitory signatures and weaker MHC-II signatures than those near GDF15-negative PLMCs. In the authors' model, MOCCI-driven OXPHOS reprogramming boosts GDF15 secretion, which acts through TGFBR2 to exhaust Tfh cells and suppress activation of neighboring B cells.
The clinical data point the same direction. In an independent cohort of 875 lung cancer cases, MOCCI expression was higher in patients with lymph node metastasis and correlated with higher nodal status. In lung adenocarcinoma cohorts, higher MOCCI expression was associated with poorer overall survival. The authors regard MOCCI as a key driver of PLMC fate and suggest its OXPHOS reprogramming could be a target for intercepting lymph node metastasis.
They are candid about limits. The multi-omics cohort included only 10 patients, and spatial heterogeneity among samples made it hard to identify shared characteristics. They call for validation in larger cohorts and further experiments on how metastases become established and how the surrounding microenvironment is remodeled. The atlas they built is offered as a resource for that work.
Notable Quotes
MOCCI-mediated OXPHOS reprogramming enhances GDF15 secretion, which acts through TGFBR2 to promote Tfh cell exhaustion and suppress neighboring B cell activation (the authors' proposed model).— Study authors, Fudan University Shanghai Cancer Center
Want the full story?
Read the original at News-Medical ↗